Prostate cancer is among the most prevalent malignancies in men. While conventional CT, MRI, and bone scans have been standard for years, they frequently miss early microscopic spread or biochemical recurrence. 68Ga-PSMA PET-CT has revolutionized urological oncology by providing receptor-targeted precision.
Why PSMA Outperforms Conventional Scans:
тАв Receptor-Specific Targeting: Binds specifically to Prostate-Specific Membrane Antigen overexpressed on 90%+ of prostate cancer cells.
тАв Ultra-Low PSA Detection: Accurately pinpoints recurrence even when serum PSA is as low as 0.2 to 0.5 ng/mL.
тАв Replaces Multiple Scans: Evaluates soft tissue, lymph nodes, and bone metastases in a single whole-body exam.
1. The Limitation of Standard 18F-FDG in Prostate Cancer
Unlike most tumors, differentiated prostate adenocarcinoma is slow-growing and has low baseline glucose metabolism. As a result, standard 18F-FDG scans often yield faint or false-negative results in prostate cancer. 68Ga-PSMA overcomes this by targeting the transmembrane protein itself rather than glucose uptake.
2. Clinical Scenarios Where PSMA Scan is Recommended
- High-Risk Initial Staging: For patients with Gleason score тЙе 8 or PSA > 20 ng/mL prior to radical prostatectomy or definitive radiation.
- Biochemical Recurrence (BCR): When PSA begins rising after surgery or radiotherapy, PSMA PET identifies the exact location of recurrence (local pelvic vs distant bones).
- Theranostics Selection (177Lu-PSMA): Screening patients who are eligible for targeted radioligand radionuclide therapy.
Dr. Neha Agrawal
Consultant Onco-Radiologist (Ex-Tata Memorial)
Dedicated to high-precision nuclear oncology imaging and patient-centric diagnostic safety at Molecular Diagnostics & Therapy Indore.